List view / Grid view
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
23 June 2016 | By Victoria White, Digital Content Producer
Amgen has announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies...
17 February 2016 | By Victoria White
Scientists have discovered the dual role of IL-36 in both promoting intestinal inflammation and resolving or healing that inflammation in IBD...
22 October 2015 | By Victoria White
The Amgen Biotech Experience was designed to inspire the next generation of innovators and give school students the opportunity to experience real science...
17 September 2015 | By Victoria White
The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb bispecific technology platform...
13 November 2014 | By Amgen
Thirteen presentations include new analyses of PCSK9 inhibitor at upcoming American Heart Association Scientific sessions...
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
12 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
5 February 2014 | By Amgen
Amgen and MSD announced that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec...
